These findings suggest that pNEN stem cell proliferation may not benefit from mTOR inhibitors alone and may justify combination therapy with multiple agents that inhibit the proliferation of both cancer cells and cancer stem cells in which mTOR signaling is inactive. Here, MTOR is linked to cancer.